1RK Stock Overview A clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Inhibrx, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Inhibrx Historical stock prices Current Share Price US$31.00 52 Week High US$38.00 52 Week Low US$13.40 Beta 2.88 1 Month Change -1.90% 3 Month Change -7.74% 1 Year Change 42.20% 3 Year Change 96.20% 5 Year Change n/a Change since IPO 14.81%
Recent News & Updates
Inhibrx Files Form 15 Jun 13 Aventis Inc. completed the acquisition of Inhibrx, Inc. (NasdaqGM:INBX) from a group of shareholders.
Inhibrx, Inc.(NasdaqGM:INBX) dropped from NASDAQ Biotechnology Index May 30
Two Separate Complaints with Nearly Identical Claims Filed in Supreme Court of State of New York, County of New York Against Inhibrx, Inc May 19
Two Separate Complaints with Nearly Identical Claims Filed in Supreme Court of State of New York, County of New York Against Inhibrx, Inc May 18
First quarter 2024 earnings released: US$1.44 loss per share (vs US$1.12 loss in 1Q 2023) May 10 See more updates
Inhibrx Files Form 15 Jun 13 Aventis Inc. completed the acquisition of Inhibrx, Inc. (NasdaqGM:INBX) from a group of shareholders.
Inhibrx, Inc.(NasdaqGM:INBX) dropped from NASDAQ Biotechnology Index May 30
Two Separate Complaints with Nearly Identical Claims Filed in Supreme Court of State of New York, County of New York Against Inhibrx, Inc May 19
Two Separate Complaints with Nearly Identical Claims Filed in Supreme Court of State of New York, County of New York Against Inhibrx, Inc May 18
First quarter 2024 earnings released: US$1.44 loss per share (vs US$1.12 loss in 1Q 2023) May 10
Full year 2023 earnings released: US$5.12 loss per share (vs US$3.62 loss in FY 2022) Feb 29
No longer forecast to breakeven Feb 29 Aventis Inc. entered into a definitive agreement to acquire Inhibrx, Inc. (NasdaqGM:INBX) for $1.4 billion. Jan 25
Aventis Inc. entered into a definitive agreement to acquire Inhibrx, Inc. (NasdaqGM:INBX) for $1.4 billion. Jan 23
New minor risk - Shareholder dilution Nov 12
Third quarter 2023 earnings released: US$1.10 loss per share (vs US$0.90 loss in 3Q 2022) Nov 11
Inhibrx, Inc. Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing Sarcoma Nov 03 Inhibrx, Inc. announced that it has received $200.000633 million in funding Sep 01
Inhibrx, Inc. announced that it expects to receive $199.999961 million in funding Aug 30
New major risk - Share price stability Aug 23
New major risk - Negative shareholders equity Aug 08
Second quarter 2023 earnings released: US$1.08 loss per share (vs US$0.97 loss in 2Q 2022) Aug 08
Inhibrx, Inc. Grants Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency May 31
First quarter 2023 earnings released: US$1.12 loss per share (vs US$0.80 loss in 1Q 2022) May 09
Full year 2022 earnings released: US$3.62 loss per share (vs US$2.15 loss in FY 2021) Mar 08
High number of new and inexperienced directors Nov 17
Inhibrx, Inc. Updates Efficacy and Safety Data from Ongoing Phase 1 INBRX-109 Expansion Cohorts for the Treatment of Chondrosarcoma Nov 17
Third quarter 2022 earnings released: US$0.90 loss per share (vs US$0.54 loss in 3Q 2021) Nov 09
Inhibrx Announces Opportunity for Accelerated Approval Pathway on Functional AAT Serum Levels for INBRX-101 in AATD and Announces Bronchoalveolar Lavage Fluid Detection Results from the Phase 1 Study Oct 05
Second quarter 2022 earnings released: US$0.97 loss per share (vs US$0.55 loss in 2Q 2021) Aug 09
Inhibrx, Inc. Announces Completion of Phase 1 Combination Dose Escalation for INBRX-105 Jul 01
High number of new and inexperienced directors Jun 01
INBRX-101 Shows Favorable Safety Profile in Patients with Alpha-1 Antitrypsin Deficiency and Demonstrates Potential to Achieve Normal Functional Alpha-1 Antitrypsin Levels with Monthly Dosing May 18
Inhibrx, Inc. to Host Webcast Presentation of Topline Results from the Phase 1 Trial of INBRX-101, its Optimized Recombinant Human AAT-Fc Protein for the Treatment of Alpha-1 Antitrypsin Deficiency May 13
First quarter 2022 earnings released: US$0.80 loss per share (vs US$0.51 loss in 1Q 2021) May 11
High number of new and inexperienced directors May 02
Inhibrx, Inc. Announces Formation of A Scientific Advisory Board for Its INBRX-101 program Apr 26
Inhibrx, Inc., Annual General Meeting, May 25, 2022 Apr 14
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Mar 02
Inhibrx, Inc. Announces Initial Phase 1 Dose Escalation Results for INBRX-106 Jan 06
Third quarter 2021 earnings released: US$0.54 loss per share (vs US$0.77 loss in 3Q 2020) Nov 10
Second quarter 2021 earnings released: US$0.55 loss per share (vs US$0.98 loss in 2Q 2020) Aug 11 Inhibrx, Inc.(NasdaqGM:INBX) dropped from Russell 3000E Value Index
Inhibrx Initiates a Potential Registration-Enabling Phase 2 Study of INBRX-109 in Conventional Chondrosarcoma Patients, Updates Data for Ongoing Phase 1 Study Jun 22
First quarter 2021 earnings released: US$0.51 loss per share (vs US$1.05 loss in 1Q 2020) May 15
Inhibrx, Inc. Announces Results from the Single Agent Dose Escalation of the Phase 1 Study of INBRX-105 Mar 14
Full year 2020 earnings released: US$3.01 loss per share (vs US$2.83 loss in FY 2019) Mar 13
Revenue beats expectations Mar 13
New 90-day low: €18.30 Mar 10
Inhibrx, Inc. Announces U.S. Food and Drug Administration Granted Fast Track Designation to INBRX-109 Jan 14
Inhibrx, Inc. Announces Results from Part 1 of the Phase 1 Dose Escalation Trial of Inbrx-106 Jan 06
Arecor's Partner Inhibrx Exercises Its Option to License A New Formulation Developed by Arecor Dec 18 Shareholder Returns 1RK DE Biotechs DE Market 7D -1.3% -3.2% 2.7% 1Y 42.2% -7.9% 17.0%
See full shareholder returns
Return vs Market: 1RK exceeded the German Market which returned 5.2% over the past year.
Price Volatility Is 1RK's price volatile compared to industry and market? 1RK volatility 1RK Average Weekly Movement 1.7% Biotechs Industry Average Movement 5.5% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.1% 10% least volatile stocks in DE Market 2.5%
Stable Share Price: 1RK has not had significant price volatility in the past 3 months.
Volatility Over Time: 1RK's weekly volatility has decreased from 8% to 2% over the past year.
About the Company Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company’s therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications.
Show more Inhibrx, Inc. Fundamentals Summary How do Inhibrx's earnings and revenue compare to its market cap? 1RK fundamental statistics Market cap €1.65b Earnings (TTM ) -€250.68m Revenue (TTM ) €1.65m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 1RK income statement (TTM ) Revenue US$1.78m Cost of Revenue US$218.11m Gross Profit -US$216.32m Other Expenses US$54.83m Earnings -US$271.15m
Last Reported Earnings
Mar 31, 2024
Earnings per share (EPS) -5.17 Gross Margin -12,132.47% Net Profit Margin -15,207.80% Debt/Equity Ratio 1,799.9%
How did 1RK perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/05/30 20:54 End of Day Share Price 2024/05/30 00:00 Earnings 2024/03/31 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github .
Analyst Sources Inhibrx, Inc. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Martin Auster Credit Suisse Joshua Schimmer Evercore ISI Michael Yee Jefferies LLC
Show 1 more analysts 